Search

Your search keyword '"Maartje A, van den Broek"' showing total 4 results
Start Over Author "Maartje A, van den Broek"
4 results on '"Maartje A, van den Broek"'

1. Effects of Liver Resection on Hepatic Short-Chain Fatty Acid Metabolism in Humans.

Author

Evelien P J G Neis, Johanne G Bloemen, Sander S Rensen, Joost R van der Vorst, Maartje A van den Broek, Koen Venema, Wim A Buurman, and Cornelis H C Dejong

Subjects
Medicine, Science
Abstract

To determine whether acute loss of liver tissue affects hepatic short-chain fatty acid (SCFA) clearance.Blood was sampled from the radial artery, portal vein, and hepatic vein before and after hepatic resection in 30 patients undergoing partial liver resection. Plasma SCFA levels were measured by liquid chromatography-mass spectrometry. SCFA exchange across gut and liver was calculated from arteriovenous differences and plasma flow. Liver volume was estimated by CT liver volumetry.The gut produced significant amounts of acetate, propionate, and butyrate (39.4±13.5, 6.2±1.3, and 9.5±2.6 μmol·kgbw-1·h-1), which did not change after partial hepatectomy (p = 0.67, p = 0.59 and p = 0.24). Hepatic propionate uptake did not differ significantly before and after resection (-6.4±1.4 vs. -8.4±1.5 μmol·kgbw-1·h-1, p = 0.49). Hepatic acetate and butyrate uptake increased significantly upon partial liver resection (acetate: -35.1±13.0 vs. -39.6±9.4 μmol·kgbw-1·h-1, p = 0.0011; butyrate: -9.9±2.7 vs. -11.5±2.4 μmol·kgbw-1·h-1, p = 0.0006). Arterial SCFA concentrations were not different before and after partial liver resection (acetate: 176.9±17.3 vs. 142.3±12.5 μmol/L, p = 0.18; propionate: 7.2±1.4 vs. 5.6±0.6 μmol/L, p = 0.38; butyrate: 4.3±0.7 vs. 3.6±0.6 μmol/L, p = 0.73).The liver maintains its capacity to clear acetate, propionate, and butyrate from the portal blood upon acute loss of liver tissue.

Published
2016
Full Text
View/download PDF

2. Hepatic Uptake of Rectally Administered Butyrate Prevents an Increase in Systemic Butyrate Concentrations in Humans

Author

Christina M, van der Beek, Johanne G, Bloemen, Maartje A, van den Broek, Kaatje, Lenaerts, Koen, Venema, Wim A, Buurman, and Cornelis H, Dejong

Subjects
Male, Dose-Response Relationship, Drug, Portal Vein, Administration, Oral, Acetates, Middle Aged, Fatty Acids, Volatile, Body Mass Index, Butyrates, Prebiotics, Liver, Humans, Female, Propionates, Aged
Abstract

Short-chain fatty acids (SCFAs), fermentation products of undigested fibers, are considered beneficial for colonic health. High plasma concentrations are potentially harmful; therefore, information about systemic SCFA clearance is needed before therapeutic use of prebiotics or colonic SCFA administration.The aim of this study was to investigate the effect of rectal butyrate administration on SCFA interorgan exchange.Twelve patients (7 men; age: 66.4 ± 2.0 y; BMI 24.5 ± 1.4 kg/m(2)) undergoing upper abdominal surgery participated in this randomized placebo-controlled trial. During surgery, 1 group received a butyrate enema (100 mmol sodium butyrate/L; 60 mL; n = 7), and the other group a placebo (140 mmol 0.9% NaCl/L; 60 mL; n = 5). Before and 5, 15, and 30 min after administration, blood samples were taken from the radial artery, hepatic vein, and portal vein. Plasma SCFA concentrations were analyzed, and fluxes from portal-drained viscera, liver, and splanchnic area were calculated and used for the calculation of the incremental area under the curve (iAUC) over a 30-min period.Rectal butyrate administration led to higher portal butyrate concentrations at 5 min compared with placebo (92.2 ± 27.0 μmol/L vs. 14.3 ± 3.4 μmol/L, respectively; P0.01). In the butyrate-treated group, iAUCs of gut release (282.8 ± 133.8 μmol/kg BW · 0.5 h) and liver uptake (-293.7 ± 136.0 μmol/kg BW · 0.5 h) of butyrate were greater than in the placebo group [-16.6 ± 13.4 μmol/kg BW · 0.5 h (gut release) and 16.0 ± 13.8 μmol/kg BW · 0.5 h (liver uptake); P = 0.01 and P0.05, respectively]. As a result, splanchnic butyrate release did not differ between groups.After colonic butyrate administration, splanchnic butyrate release was prevented in patients undergoing upper abdominal surgery. These observations imply that therapeutic colonic SCFA administration at this dose is safe. The trial was registered at clinicaltrials.gov as NCT02271802.

Published
2015

3. A traumatic false aneurysm of the ankle: an unusual bump on the forefoot

Author

Maartje A van den Broek, Ewan D Ritchie, Hugo T.C. Veger, Paul Ph Hedeman Joosten, and Willem-Maarten Bosman

Subjects
Male, medicine.medical_specialty, medicine.diagnostic_test, business.industry, Forefoot, Ultrasound, Atrial fibrillation, Physical examination, General Medicine, medicine.disease, Article, Tibial Arteries, medicine.anatomical_structure, Aneurysm, Dorsalis pedis artery, medicine.artery, medicine, Humans, Medical history, Radiology, Ankle Injuries, Ankle, business, Aneurysm, False, Aged
Abstract

A 66-year-old man was referred to the general surgeon by his general practitioner for excision of a ‘bump’ on the anterior side of his left ankle because of pain due to irritation from shoe gear. This ‘bump’ slowly started since several months after an ankle injury. He denies intravenous access or previous surgery in this region of the ankle. Medical history represents obesity, atrial fibrillation, chronic obstructive pulmonary disease and diabetes mellitus type 2. Physical examination of the left ankle revealed an elevated, weak pulsatile mass approximately 2 cm in diameter. It was located along the anterior side of the left ankle in the anatomical region of the dorsalis pedis artery (DPA). MR angiography and MRI (figure 1A, B) and duplex ultrasound (figure …

Published
2014

4. Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases

Author

Celien P H, Vreuls, Maartje A, Van Den Broek, Alison, Winstanley, Ger H, Koek, Eddie, Wisse, Cornelis H, Dejong, Steven W M, Olde Damink, Fred T, Bosman, and Ann, Driessen

Subjects
Adult, Male, Organoplatinum Compounds, Liver Neoplasms, Hepatic Veno-Occlusive Disease, Antineoplastic Agents, Middle Aged, Combined Modality Therapy, Neoadjuvant Therapy, Oxaliplatin, Treatment Outcome, Hepatectomy, Humans, Female, Prospective Studies, Colorectal Neoplasms, Aged
Abstract

Oxaliplatin is an important chemotherapeutic agent used to reduce hepatic colorectal metastases, resulting in tumour reduction and permitting surgical resection. This treatment has significant side effects, as oxaliplatin can induce sinusoidal obstruction syndrome (SOS) in the non-tumour-bearing liver, resulting in increased morbidity. We hypothesized that SOS might impede hepatic perfusion, thereby interfering with the tumour environment and attenuate the response to the chemotherapy.From the prospective database of the Maastricht University Medical Centre we collected 50 patients with hepatic colorectal carcinoma metastases. All patients received neo-adjuvant oxaliplatin followed by partial hepatectomy. Metastases and non-tumour-bearing liver were studied histopathologically. Thirty-two of 50 (64%) patients showed SOS lesions, classified as mild (26%) and moderate-severe (38%). The response to treatment, as expressed in the tumour regression grade (TRG), was grade 1 (10%); grade 2 (14%); grade 3 (28%); grade 4 (32%) and grade 5 (16%). Statistical analysis showed that a higher grade of SOS was associated with a higher grade of TRG (P = 0.016).Developing SOS is associated with a lower tumour response to neo-adjuvant oxaliplatin treatment. Hepatic hypoperfusion due to sinusoidal obstruction syndrome might induce hepatic hypoxia, diminishing the response to chemotherapy.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results